# US 10,307,432 B2 · Stabilized liquid fosaprepitant formulations > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,307,432 B2 - Document ID: US10307432B2 - Status: Granted - Kind: B2 - Application number: 15/886,247 - Filed: 2018-02-01 - Published: 2018-06-07 - Granted: 2019-06-04 - Earliest claimed: 2015-11-03 - Assignees: Cipla Limited - Applicants: Cipla Limited - Inventors: Geena Malhotra; Sarabjit Singh; Abhijit Jadhav - Web page: https://patentgrep.com/patent/US10307432B2 ## CPC - A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame} - A61K 9/08: Solutions {(composition of solutions A61K47/00)} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention relates to stable pharmaceutical compositions of fosaprepitant or a salt thereof in the form of ready-to-use or ready-to-dilute compositions suitable for parenteral administration. ## Claims ### Claim 1 A liquid composition comprising: fosaprepitant or a salt thereof, an aqueous albumin vehicle, and at least one stabilizer selected from fatty acid metal salts, antioxidants, and chelating agents, wherein after storage at 2-8° C. for at least 1 month, aprepitant is present in an amount concentration of no more than 10%. ### Claim 2 (depends on 1) The liquid composition according to claim 1, comprising a chelating agent selected from the group consisting of ethylenediaminetetraacetic acid, hydroxyethylethylenediaminetriacetic acid, diethylenetriaminepentaacetic acid, nitrilotriacetic acid, ethanol diglycine, 1,3-propylenediaminetetraacetic acid, or a pharmaceutically acceptable salt thereof. ### Claim 3 (depends on 2) The liquid composition according to claim 2, wherein the chelating agent comprises ethylenediaminetetraacetic acid or pharmaceutically acceptable salt thereof. ### Claim 4 (depends on 1) The liquid composition according to claim 1, wherein the aqueous albumin vehicle comprises a 25% aqueous albumin vehicle. ### Claim 5 (depends on 1) The liquid composition according to claim 1, wherein the fosaprepitant is fosaprepitant dimeglumine. ### Claim 6 (depends on 1) The liquid composition according to claim 1, further comprising an additional agent for the treatment of chemotherapy-induced nausea and vomiting (CINV). ### Claim 7 (depends on 6) The liquid composition according to claim 6, wherein the additional agent comprises a corticosteroid, a 5HT3 receptor antagonist, GABAB receptor agonist, or a combination thereof. ### Claim 8 (depends on 7) The liquid composition according to claim 7, wherein the additional agent comprises dexamethasone, triamcinolone, flunisolide, budesonide, palonosetron, ondansetron, granisetron, tropisetron, decadron, zatisetron, or baclofen. ### Claim 9 (depends on 1) A method of treating chemotherapy-induced nausea and vomiting (CINV), wherein the method comprises administering a liquid pharmaceutical composition according to claim 1. ### Claim 10 (depends on 9) The method according to claim 9, comprising administering at least one additional agent for the treatment of chemotherapy-induced nausea and vomiting (CINV). ### Claim 11 (depends on 10) The method according to claim 10, wherein the additional agent comprises dexamethasone, triamcinolone, flunisolide, budesonide, palonosetron, ondansetron, granisetron, tropisetron, decadron, zatisetron, baclofen, or a combination thereof. ### Claim 12 A liquid composition comprising fosaprepitant or a salt thereof, a solubilizer comprising at least one alcohol, at least one glycol, or a combination thereof, wherein after storage at 2-8° C. for at least 1 month, aprepitant is present in an amount concentration of no more than 10%, wherein the composition is ready-to-use or ready-to-dilute. ### Claim 13 (depends on 12) The liquid composition according to claim 12, wherein the alcohol comprises ethanol, octanol, glycofurol or a mixture thereof. ### Claim 14 (depends on 12) The liquid composition according to claim 12, comprising a glycol comprising propylene glycol, glycerol, polyethylene glycol, or a mixture thereof. ### Claim 15 (depends on 12) The liquid composition according to claim 12, comprising ethanol and propylene glycol. ### Claim 16 (depends on 12) The liquid composition according to claim 12, further comprising an additional agent for the treatment of chemotherapy-induced nausea and vomiting (CINV). ### Claim 17 (depends on 12) The liquid composition according to claim 12, wherein the additional agent comprises a corticosteroid, a 5HT3 receptor antagonist, GABAB receptor agonist, or a combination thereof. ### Claim 18 (depends on 12) The liquid composition according to claim 12, wherein the additional agent comprises dexamethasone, triamcinolone, flunisolide, budesonide, palonosetron, ondansetron, granisetron, tropisetron, decadron, zatisetron, or baclofen. ### Claim 19 (depends on 12) A method of treating chemotherapy-induced nausea and vomiting (CINV), wherein the method comprises administering a liquid pharmaceutical composition according to claim 12. ### Claim 20 (depends on 19) The method according to claim 19, comprising administering at least one additional agent for the treatment of chemotherapy-induced nausea and vomiting (CINV). ### Claim 21 (depends on 20) The method according to claim 20, wherein the additional agent comprises dexamethasone, triamcinolone, flunisolide, budesonide, palonosetron, ondansetron, granisetron, tropisetron, decadron, zatisetron, baclofen, or a combination thereof.